Abstract
Current guidelines (ie, by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer) do not recommend secondary infection prophylaxis, whereas, in contrast, caregivers prefer secondary prophylaxis to chemotherapy dose reduction after an episode of febrile neutropenia (FN). Because granulocyte colony-stimulating factor (G-CSF) is expensive, this study investigates the economic consequences of secondary prophylactic use of different prophylactic strategies (antibiotics, antibiotics plus G-CSF, and a combined sequential approach) in a population at risk of FN, using a Markov model. The input for the model is mainly based on the clinical outcome and patient-based cost data set (adopting the health care payer's perspective for the Netherlands) derived from a randomized study on primary prophylaxis in small-cell lung cancer (SCLC) patients; establishing mean cost of an episode FN of euro3,290 and prophylaxis of euro79 (antibiotics) +/- euro1,616 (G-CSF) per cycle. The economic analysis was analyzed probabilistically using first- and second-order Monte Carlo simulation. The incremental cost-effectiveness ratio (ICER) was defined as cost per FN-free cycle. Secondary prophylaxis with a...Continue Reading
References
Jul 18, 1991·The New England Journal of Medicine·J CrawfordG Rausch
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L BennettH B Niell
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Trillet-LenoirD Tomita
Sep 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L BennettR J Winn
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H GómezC Vallejos
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C ChouaidB Housset
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V C Tjan-HeijnenUNKNOWN European Organisation for Research and Treatment of Cancer-Lung Cancer Group
Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young
Aug 21, 2002·Expert Opinion on Pharmacotherapy·Jared R AdamsCharles L Bennett
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea ArdizzoniUNKNOWN European Organization for Research and Treatment of Cancer-Lung Cancer Group
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V C G Tjan-HeijnenUNKNOWN European Organisation for Research Treatment of Cancer-Lung Cancer Group and Health Economics Unit
Nov 19, 2003·Pharmacotherapy·Luis A MezaFrankie A Holmes
Aug 27, 2004·PharmacoEconomics·Robert WelteReiner Leidl
Aug 20, 2005·Medical Oncology·Nissim HaimMedy Tsalic
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna N Timmer-BonteVivianne C Tjan-Heijnen
Apr 1, 2006·Cancer·Nicole M KudererGary H Lyman
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna N H Timmer-BonteVivianne C G Tjan-Heijnen
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gianluigi Ferretti, Paola Papaldo
May 2, 2007·The Oncologist·Charles L Bennett, Elizabeth A Calhoun
Citations
Jun 30, 2010·Cell Biochemistry and Biophysics·Yimei FengLei Gao
Jul 8, 2008·International Journal of Technology Assessment in Health Care·Amelia CompagniEmma Gutierrez de Mesa
May 27, 2011·The New England Journal of Medicine·Thomas J Smith, Bruce E Hillner
Jun 25, 2009·Current Opinion in Supportive and Palliative Care·David C Dale
Nov 13, 2008·Journal of Veterinary Internal Medicine·D B BaileyC E Balkman
May 18, 2011·Onkologie·Angela Ihbe-HeffingerVolker R Jacobs
May 1, 2012·PharmacoEconomics·Bradford R Hirsch, Gary H Lyman
Jan 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of Americaa
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Feb 25, 2009·Critical Reviews in Oncology/hematology·John R Wingard, Mohamed Elmongy
Nov 1, 2014·Thoracic Cancer·Chun-Ru ChienChih-Yi Chen
Aug 6, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Ippei TakeuchiHiroyuki Kamei
Jun 3, 2016·Pediatrics in Review·Jennifer Lighter-FisherLiana M Klejmont
Jan 10, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Kelly FustMilton C Weinstein
Jul 9, 2009·The Annals of Pharmacotherapy·Laura Boehnke Michaud
Apr 7, 2018·PharmacoEconomics Open·Ashley EnstoneYong Yuan
Nov 11, 2017·International Journal of Technology Assessment in Health Care·Mathilda L BongersVeerle M H Coupé
May 1, 2009·Internal Medicine Journal·I E Haines, I Olver